RESPIRONICS, INC. DEMONSTRATION, EVALUATION, AND SAMPLE POLICY

Similar documents
RESPIRONICS, INC. CONTRACTING WITH HEALTHCARE PROFESSIONALS OR PROVIDERS AND REFERRAL SOURCES POLICY

RESPIRONICS, INC. FOCUS ARRANGEMENTS AND PROMOTIONAL FUNCTIONS POLICY

RESPIRONICS, INC. CORPORATE HEALTHCARE COMPLIANCE PROGRAM POLICY

Provider and Provider Relationships. Primary Fraud and Abuse Issues

Manufacturer Patient Support Initiatives: Current Practices and Recent Challenges. Andrew Ruskin Morgan Lewis

Investigator Compensation: Motivation vs. Regulatory Compliance

Law Department Policy No. L-8. Title:

Payment Policy: Code Editing Overview Reference Number: CC.PP.011 Product Types: ALL Effective Date: 01/01/2013 Last Review Date: 06/28/2018

DETERMINING FAIR MARKET VALUE FOR SERVICES RENDERED BY A DESIGNATED COLLABORATING ORGANIZATION

Lifetime Limits Effective September 23, 2010, payors are prohibited from placing lifetime dollar limits on medical claims.

2014 Lathrop & Gage LLP Lathrop & Gage LLP Lathrop & Gage LLP

Stark Law Exceptions and Anti-Kickback Safe Harbors

Compensation Paid by Healthcare Providers

Fair Market Value Implications for Sleep Transactions National Sleep Foundation

Texas Medicaid. Provider Procedures Manual. Provider Handbooks. Certified Respiratory Care Practitioner (CRCP) Services Handbook

Stryker Sales Corporation Acting through its Endoscopy division

7/25/2018. Government Enforcement in the Clinical Laboratory Space. The Statutes & Regulations. The Stark Law. The Stark Law.

Phase II CORE 260 Eligibility and Benefits (270/271) Data Content Rule Appendix 6.2 Glossary of Terms version March 2011

Law Department Policy No. L-25 Title:

ACO LEGAL ISSUES. Carson P. Porter Rimon Law Group

Law Department Policy No. L-16 Title:

Medicare Part B Payment Systems for DMEPOS

This policy applies to all Napo associates who may provide a meal to a healthcare professional.

FRAUD AND ABUSE LAW IMPLICATED BY COMPENSATION ARRANGEMENTS. Lee Rosebush, PharmD, RPh, MBA, JD

S ark L aw aw An A t n i-kickbac b k S atut u e an an d Fal F se Cl C aims A c A t E f n orcement Jay y P. P A n A sti t n i e, e JD R adma m p

Hospital Incentive Payments to Physicians for Quality and Cost Savings

Hancock, Daniel & Johnson, P.C., P.O. Box 72050, Richmond, VA , ,

PURCHASING INTERNET LEADS: SURE, IT CAN BE DONE, BUT BE VERY CAREFUL. Denise Leard, Esq Brown & Fortunato, P.C.

OFFICE OF INSPECTOR GENERAL'S COMPLIANCE PROGRAM GUIDANCE FOR THE DURABLE MEDICAL EQUIPMENT, PROSTHETICS, ORTHOTICS, AND SUPPLY INDUSTRY

FCA Settlement Raises Questions For Health IT

Health Law 101: Issue-Spotting In Dealing With Health-Care Providers. by William H. Hall Jr.

Prevention Of Corruption

(1) Ambulatory surgical center (ASC) means any center, service, office facility, or other entity that:

Global Compliance Policy on Due Diligence and Interactions with Third Party Representatives

Sender's Direct Phone (202) Sender's Direct Facsimile (202) MEMORANDUM

42 CFR Ch. IV ( Edition)

Contracting with Specialty Pharmacies and Hubs 17 th Annual Pharma and Medical Device Compliance Congress. October 20, 2016

CHAPTER 32. AN ACT concerning health insurance and health care providers and supplementing various parts of the statutory law.

Check Your Physician Contracts

Physician Contracts GOVERNANCE THOUGHT LEADERSHIP SERIES

Document Type Doc ID Status Version Page/Pages. Policy LDMS_001_ Effective of 11 Title: Global Policy on Ethical Interactions

The Challenge of Implementing Interoperable Electronic Medical Records

RULES OF TENNESSEE DEPARTMENT OF LABOR AND WORKFORCE DEVELOPMENT DIVISION OF WORKERS COMPENSATION

HEALTH CARE FRAUD. EXPERT ANALYSIS HHS OIG Adopts New Anti-Kickback Safe Harbor and Civil Monetary Penalty Exceptions

Practical Considerations for Medical Practices Considering Converting Their Vascular Access Centers Into Medicare-Certified Ambulatory Surgery Centers

Glossary of Definitions

Anti-Kickback Statute Jess Smith

Stark and the Anti Kickback Statute. Regulating Referral Relationship. February 27-28, HCCA Board Audit Committee Compliance Conference.

WHAT EVERY NEW PRACTITIONER SHOULD CONSIDER

Supplemental Special Advisory Bulletin: Independent Charity. Patients who cannot afford their cost-sharing obligations

PHYSICIAN INVESTMENT COMPLIANCE

Ridgecrest Regional Hospital Compliance Manual

Medicare Transition POLICY AND PROCEDURES

Telemedicine Fraud and Abuse Under the Microscope

Dear Colleague, In the steadfast pursuit of excellence, I remain, Sincerely yours,

This Webcast Will Begin Shortly

2019 Transition Policy and Procedure

Top 10 Issues in APM Contract Negotiations

Medicare Parts C & D Fraud, Waste, and Abuse Training and General Compliance Training

An Introduction to Medicare

Physician Rockstars Toolkit - Common Models and Legal Considerations for Securing the Services of Rockstar physicians. Item 3

DEPARTMENT OF HEALTH AND HUMAN SERVICES. Office of Inspector General s Use of Agreements to Protect the Integrity of Federal Health Care Programs

Chapter 1: A Distinctive System of Health Care Delivery

Physician Contracting An Overview of Legal Policy No. 9

Durable medical equipment, prostheses, orthoses, and supplies (DMEPOS): general provisions.

Developed by the Centers for Medicare & Medicaid Services Issued: February, 2013

B. promotes patient safety and ease of care; and

HEALTHCARE BULLETIN. July 8, 2008 CMS PROPOSES NEW STARK EXCEPTION FOR INCENTIVE PAYMENT AND SHARED SERVICES PROGRAMS

thirty report. hospital was that Position Support should or should effect until revoked.

Chapter 11 Section 12.1

I. PURPOSE. A. The primary objectives of Molina Healthcare s Transition Policy and Procedure are:

Federal Fraud and Abuse Enforcement in the ASC Space

The Impact of the Fraud and Abuse Laws on Pharmaceutical Advertising and Marketing Compliance: A Manufacturer s Perspective

Regulatory Compliance Policy No. COMP-RCC 4.21 Title:

Health Care Compliance Association

Ensuring Compliance with the Law - Properly Structuring Innovative Marketing and Creative Joint Ventures. Top 5 Things to Know for CE:

Ensuring Compliance with the Law - Properly Structuring Innovative Marketing and Creative Joint Ventures. Clay Stribling, Esq.

Industry Funding of Continuing Medical Education

Medicaid Program; Disproportionate Share Hospital Payments Uninsured Definition

44 NJR 2(2) February 21, 2012 Filed January 26, Proposed Amendments: N.J.A.C. 11:4-37.4; 11:22-4.2, 4.3, 4.4, and 4.5;

Texas Vendor Drug Program. Drug Addition Process. Effective Date. December 2017

ProviderNews PLEASE SHARE WITH YOUR APPROPRIATE CLINIC PERSONNEL December 2015

Blue Select Policy Comparison Chart Effective January 1, 2018 Blue Select Part A Hospital Insurance Covered Services

Medicare Parts C & D Fraud, Waste, and Abuse Training

Stark Law Exceptions and Anti-Kickback Safe Harbors

MEDICARE PRESCRIPTION DRUG PART D COMPLIANCE CONFERENCE. Reporting Requirements: Audit Preparedness for PDPs and Manufacturers

LAWS OF ALASKA AN ACT

OIG 125 N: Solicitation of New Safe Harbors and Special Fraud Alerts

Amgen GLOBAL CORPORATE COMPLIANCE POLICY

Connecticut interchange MMIS

Guide to Medicare Coverage Who qualifies for Medicare benefits? Individuals 65 years of age or older Individuals under 65 with permanent kidney

H e a l t h C a r e Compliance Adviser

Provider Dispute/Appeal Procedures

PI Compensation: Methods, Documentation, and Execution

PI Compensation: Methods, Documentation, and Execution

SIGNIFICANT PROPOSED CHANGES TO THE ANTI- KICKBACK STATUTE AND THE CIVIL MONETARY PENALTIES LAW

Annual Notice of Changes for 2017

Code on Global Interactions. with Healthcare Professionals

Product Reimbursement Services and Patient Assistance Programs KATHY CHAURETTE ALESSANDRO MARTUSCELLI

BlueCare Policy Comparison Chart Effective January 1, 2019 BlueCare Part A Hospital Insurance Covered Services

Transcription:

Page 1 of 5 I. Purpose RESPIRONICS, INC. DEMONSTRATION, EVALUATION, AND SAMPLE POLICY The provision of Products to Healthcare Providers ( HCPs ) for Evaluation and Demonstration purposes can benefit patients in many ways, including but not limited to: Improving patient care; Improving patient adherence; Educating HCPs regarding the use of Products or technology; and Increasing the safe and effective use of Products. This document sets forth Respironics, Inc. s ( Company ) policy concerning the distribution of Products at no charge to facilitate HCPs or patients Evaluation or Demonstration of the use of the Product. II. Scope This Policy applies to: Company, including both its business group and U.S. and U.S. territories sales activities, and their officers, directors, and employees, and Company s consultants, contract workers, and temporary workers, who provide services to Company, which relate to government reimbursed Products or services; and The distribution and accountability of Evaluation and Demonstration units (including Product samples) and services. III. Definitions Centralized Arrangements Tracking Systems ( CATS ) SharePoint: The database that serves as the electronic repository for Company s Focus Arrangements, including signed agreements, and supporting documentation. Demonstration: An Company representative s or an HCP s use of serialized (Trunk Stock) and nonserialized product to train or educate customers, in topics such as Product use and features and general awareness about the disease that the Product is designed to treat and the treatment it provides. Evaluation or Evaluate: A customer s or clinician s, use of a Product to (a) assess the appropriate use and functionality of the Product, (b) determine whether to use, order, purchase, lease, or recommend the Product, or (c) train patients on the use of the Product or allow patients to use the Product for their own evaluation purposes. Evaluation equipment converts to sale if not within returned within evaluation period.

Page 2 of 5 Healthcare Professional or Provider ( HCP ) or Potential Referral Source: The term U.S. Healthcare Professional is defined very broadly to cover any person or entity that is involved in the provision of healthcare services or items to patients, and that purchases, leases or recommends, uses or arranges for the purchase or lease, of Company medical Products, services, or solutions in the U.S. Practically, this includes, among others: Clinicians, such as physicians, nurses, PhDs, technologists, pharmacists, and medical staff, such as respiratory technologists or physician assistants, as well as clinicians in training. Hospitals, medical schools affiliated with hospitals, medical group practices, medical clinics, nursing homes, sleep diagnostic clinics, surgical centers, emergency medical services and home healthcare organizations, as well as nonmedical personnel in these facilities who make purchasing decisions. Medical device distributors and dealers, including durable medical equipment ( DME ) suppliers, who sell to HCPs or bill Medicare and Medicaid for their items and services. Healthcare-related trade associations which serve HCPs or have a significant number of HCPs on its board, such as the American Sleep Association. Employees, administrators, officers, and directors of HCPs are also considered HCPs, where involved in the decision to purchase or lease Company services or Products. Product: Devices, medical supplies, equipment, software, and services provided by Company. Respironics Code of Conduct ( COC ): Consists of three distinct policies: SimplyRight, Philips General Business Principles, and Code of Conduct on Interactions with Healthcare Professionals (collectively, Code of Conduct ). Respironics Compliance Officer ( CO ): Primarily responsible for overseeing and managing the Company s Corporate Healthcare Compliance Program and related Corporate Integrity Agreement, and monitoring that the Company and its employees for compliance are complying with applicable regulatory, legal, and compliance requirements including internal policies and procedures, as well as external regulations and codes of conduct. Sample: Non-serialized product provided to a customer or patient for single use or single-patient use for Evaluation and Demonstration purposes, such as masks. Shell unit: base built products in which the interior core is removed or qualifies as non-functional, which are provided to customers for the purpose of educating patients on the use and function of the product. IV. Policy Trunk Stock: serialized equipment that resides with a rep that is not sold to or left with a customer. Company personnel may provide Products at no charge for the period of time and volume permitted Policy solely for Evaluation or Demonstration purposes pursuant to internal policies and procedures including the Sample Policy.

Page 3 of 5 Company personnel may not: (a) provide Products or services to HCPs for free to improperly induce the purchase of any Philips Products; (b) commit to provide Evaluation or Demonstration Products in connection with a purchase commitment, except as permitted under this Policy; (c) provide a Sample, Evaluation and Demonstration Product to an HCP for his/her personal use or for use by his/her immediate family or office staff; and Items identified for Demonstration use shall not be converted for Evaluation purposes. Company must include language reminding customer of their obligation, where appropriate, to NOT bill or seek reimbursement if patient care is predicated on the use of Evaluation Products, including Samples. A. Volume Limits Evaluation Products and Samples The number of Evaluation Products and Samples that Company may provide at no charge may not exceed the amount reasonably necessary for the adequate Evaluation of the Products under the circumstances. Separate quantity limits may apply for Products intended for HCP Evaluation and for patient Evaluation. Company will establish quantity limits, which must be approved Chief Medical Liaison, the Compliance Officer ( CO ), and Company s Legal Department. B. Duration of Use Evaluation of Products, Services and Software Non-consumable Products or software and associated services may be provided to HCPs without transfer of title for Evaluation purposes, but only for a period of time that is reasonable under the circumstances to allow an adequate Evaluation, which the Company has established to be 60 (sixty) days for Products, and 90 (ninety) days for software and services. In no circumstances should the Evaluation period exceed 90 (ninety) days without prior written approval from Company Legal Department and CO. Company must establish and maintain a process for promptly removing such Products or software or services from an HCP s location at the conclusion of the Evaluation period, unless the HCP purchases or leases the Product upon the expiration of the Evaluation Period. C. Frequency and Circumstances Evaluation Product Company has determined that the distribution of free Product for Evaluation or Demonstration purposes is permitted in the following circumstances: New Product introduction Product upgrades

Page 4 of 5 Clinician turnover Clinician competency gaps reestablish clinician competency after a given time since the last Product training HCP lacks familiarity with a Product and wishes to evaluate it before making a purchasing decision. Prior to providing any Product for Evaluation or Demonstration, Company must provide the customer general Product awareness training and any standard Product training applicable to the Product and an agreement that addresses the terms of the Evaluation. D. Marking of Demonstration Products and Samples Demonstration Products are typically single patient use Products or mockups of such Products that are used for HCP and patient awareness, education, and training. For example, a HCP may use a Demonstration Product to show a patient the type of device that will be used by the patient. Demonstration Products not intended for patient use must be identified by such designations as "Demo Only" "Not for Human Use," or other suitable designation on the Product, the Product packaging, or Product documentation. If a Product is given as a Sample for Evaluation Purposes, the Product must be marked as Sample Not for Resale and tracked in CATS.. E. Required Documentation IV. Appendices Company must provide documentation reflecting the provision and receipt of the no-charge Products for Evaluation or Demonstration purposes. For Evaluation products, such terms shall include, at a minimum: (i) language requiring the return of, and authorizing Company access to secure the return of, multiple-use products upon the conclusion of the Evaluation period, unless the customer otherwise elects to purchase or lease the Product; and (ii) when appropriate, language reminding customer of their obligation to NOT bill or seek reimbursement if patient care is predicated on the use of products. For Demonstration products, when appropriate, language reminding customers of their obligation to NOT bill or seek reimbursement if patient case is predicated on the use of products. Not Applicable V. References Anti-Kickback Statute, 42 U.S.C. 1320a-7b(b) Referenced Documents:

Page 5 of 5 Document Number Not Applicable Document Description